On the whole, we report the possibility of specifically targeting FLT3-ITD+ AML cells by inducing proteotoxic stress with the combination RBA plus ascorbic acid, all drugs already in use in clinical practice in different settings. Here, FLT3 is linked to acute myeloid leukemia.